Radiotherapy quality assurance in the TROG 12.01 randomised trial and its impact on loco-regional failure.

head and neck (H&N) cancer human papilloma virus - HPV intensity modulated radiotherapy (IMRT) quality assurance radiotherapy

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 04 11 2023
accepted: 20 12 2023
medline: 20 2 2024
pubmed: 20 2 2024
entrez: 20 2 2024
Statut: epublish

Résumé

There is no consensus as to what specifically constitutes head and neck cancer radiotherapy quality assurance (HNC RT QA). The aims of this study are to (1) describe the RT QA processes used in the TROG 12.01 study, (2) review the RT QA processes undertaken for all patients with loco-regional failure (LRF), and (3) provide prospective data to propose a consensus statement regarding the minimal components and optimal timing of HNC RT QA. All patients undergoing RT QA in the original TROG 12.01 study were included in this substudy. All participating sites completed IMRT credentialling and a clinical benchmark case. Real-time (pre-treatment) RT QA was performed for the first patient of each treating radiation oncologist, and for one in five of subsequent patients. Protocol violations were deemed major if they related to contour and/or dose of gross tumour volume (GTV), high dose planning target volume (PTVhd), or critical organs of risk (spinal cord, mandible, and brachial plexus). Thirty HNROs from 15 institutions accrued 182 patients. There were 28 clinical benchmark cases, 27 pre-treatment RT QA cases, and 38 post-treatment cases. Comprehensive RT QA was performed in 65/182 (36%) treated patients. Major protocol violations were found in 5/28 benchmark cases, 5/27 pre-treatment cases, and 6/38 post-treatment cases. An independent review of all nine LRF cases showed major protocol violations in four of nine cases. Only pre-treatment RT QA can improve patient outcomes. The minimal components of RT QA in HNC are GTVs, PTVhd, and critical organs at risk. What constitutes major dosimetric violations needs to be harmonised.

Identifiants

pubmed: 38375205
doi: 10.3389/fonc.2023.1333098
pmc: PMC10875123
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1333098

Informations de copyright

Copyright © 2024 Corry, Moore, Kenny, Wratten, Fua, Lin, Porceddu, Liu, Ruemelin, Sharkey, McDowell, Wilkinson, Tiong and Rischin.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

June Corry (J)

Genesiscare Radiation Oncology Department, St Vincents Hospital, Melbourne, VIC, Australia.
Department Medicine, University of Melbourne, Melbourne, VIC, Australia.
Department Radiation Oncology, Peter MacCallum Cancer Center, Melbourne, VIC, Australia.

Alisha Moore (A)

Department Radiation Quality Assurance, Trans-Tasman Radiation Oncology Group (TROG), Newcastle, NSW, Australia.

Liz Kenny (L)

Department Radiation Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
Faculty Medicine, University of Queensland, Brisbane, QLD, Australia.

Chris Wratten (C)

Department Radiation Oncology, Calvary Mater Hospital and University Newcastle, Newcastle, NSW, Australia.

Tsien Fua (T)

Department Radiation Oncology, Peter MacCallum Cancer Center, Melbourne, VIC, Australia.

Charles Lin (C)

Department Radiation Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.

Sandro Porceddu (S)

Department Radiation Oncology, Princess Alexander Hospital, Brisbane, QLD, Australia.

Chen Liu (C)

Department Radiation Oncology, Peter MacCallum Cancer Center, Melbourne, VIC, Australia.

Michael Ruemelin (M)

Department Radiation Therapy, Peter MacCallum Cancer Center, Melbourne, VIC, Australia.

Amy Sharkey (A)

Department Radiation Therapy, Peter MacCallum Cancer Center, Melbourne, VIC, Australia.

Lachlan McDowell (L)

Department Radiation Oncology, Peter MacCallum Cancer Center, Melbourne, VIC, Australia.

Dean Wilkinson (D)

Department Radiation Therapy, Illawarra Cancer Care Centre, Wollongong, NSW, Australia.

Albert Tiong (A)

Department Radiation Oncology, Peter MacCallum Cancer Center, Melbourne, VIC, Australia.

Danny Rischin (D)

Department Medical Oncology, Peter MacCallum Cancer Center, Melbourne, VIC, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.

Classifications MeSH